Skip to main content

Table 1 Protease inhibitor exposure and current therapy details of the 82 patients (88 resistance tests)

From: It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Prior PI exposure

PI or NNRTI component at the time of resistance testing

PI (n = 53)

LPV/r

(n = 30)

LPV/r (n = 30)

 

RTV

(n = 23)

LPV/r (n = 16)

  

LPV/r+ NVP (n = 1)

  

EFV (n = 4)

  

RTV (n = 2)

No PI

(n = 29)

 

EFV (n = 17)

  

NVP (n = 11)

  

EFV or NVP at different time points(n = 1)

  1. PI: Protease inhibitor
  2. NNRTI: Non-nucleoside reverse transcriptase inhibitor
  3. Nevirapine: NVP
  4. Efavirenz: EFV
  5. Ritonavir: RTV
  6. At testing, 53 patients had PI exposure. Of these, 47 were treated with PIs (45 with LPV/r and 2 with RTV) and 5 with EFV and 1 with LPV/r plus NVP. Twenty-nine without PI exposure were treated with NNRTIs (17 with EFV, 12 with NVP and one with either NVP or EFV at different time points). Twenty-three patients had received RTV sPI, of whom16 had been switched to LPV/r and one to NVP plus LPV/r. Four were switched to EFV and two remained on RTV at the time specimens were submitted.
Back to article page

Journal of the International AIDS Society

ISSN: 1758-2652